The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
Benjamin L. Handen, Ira T. Lott, Bradley T. Christian, Nicole Schupf, Sid E. O’Bryant, Mark Mapstone, Anne M. Fagan, Joseph H. Lee, Dana Tudorascu, Mei‐Cheng Wang, Elizabeth Head, William E. Klunk, Beau M. Ances, Florence Lai, Shahid Zaman, Sharon J. Krinsky‐McHale, Adam M. Brickman, H. Diana Rosas, Annie Cohen, Howard Andrews, Sigan L. Hartley, Wayne Silverman
Abstract
INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. METHODS: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. RESULTS: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. DISCUSSION: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.